Clinical Trial

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
Protocol Amendment History 3 changes
notable Trial sites expanded: 32 -> 35 locations 2026-08-05
notable Trial sites expanded: 24 -> 30 locations 2026-06-17
notable Trial sites expanded: 20 -> 24 locations 2026-05-29
Trial Details
NCT Number NCT07221500
Lead Sponsor Nurix Therapeutics, Inc.
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Enrollment 100 participants
Start Date 2025-10-15
Primary Completion 2028-01 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-04